GNAQ and cancer: CysLT1 antagonists alter MAPK signaling in Mel285 primary UM cells, as reported in other cancer and non-cancer cell types (21, 30, 31), but not in metastatic OMM2.5 UM cells bearing a Gaq Q209P mutation that constitutively activates ERK (32).